MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2019 International Congress

    Pre-diagnosis physical activity habits are associated with age of diagnosis and postural instability in Parkinson’s disease

    M. Landers, K. Johnson, S. Johnson, J. Lyle, T. Ormsby, D. Salgo, J. Zorn, A. Murtishaw, A. Salazar, J. Kinney (Las Vegas, NV, USA)

    Objective: To determine if pre-diagnosis exercise and brain-derived neurotrophic factor (BDNF) genotype are predictive of age at diagnosis and severity of balance impairment. Background: Studies…
  • 2019 International Congress

    Park-Ease Trial: A Randomized Controlled Trial to Study the Efficacy of Exercises in Early-Stage Parkinson’s Disease

    R. Swarnakar, S. Wadhwa, S. V, V. Goyal, V. Sreenivas (New Delhi, India)

    Objective: To evaluate the efficacy of exercises in early-stage Parkinson’s Disease by observing improvement in motor symptoms assessed by Unified Parkinson’s Disease Rating Scale (UPDRS)…
  • 2019 International Congress

    Investigation into the causes of reduced caffeine levels in Parkinson’s disease

    MI. de Bartolo, G. Leodori, A. Fabbrini, M. Costanzo, D. Belvisi, A. Conte, S. Manetto, A. Ciogli, C. Villani, A. Berardelli, G. Fabbrini (Rome, Italy)

    Objective: To find out whether PD patients show decreased salivary caffeine levels; to investigate CYP1A2-phenotype and caffeine absorption as possible causes of decreased caffeine levels…
  • 2019 International Congress

    Limitations of Curcumin as a Therapeutic Agent in Rotenone Induced Dopaminergic Neurodegeneration: Insights from Drosophila Model of Parkinson’s Disease

    M. Ayajuddin, SC. Yenisetti (Zunheboto, India)

    Objective: To understand the efficacy of curcumin in rotenone induced Drosophila model of Parkinson’s disease. Background: Parkinson’s disease (PD) is the second most common neurodegenerative…
  • 2019 International Congress

    Neuroprotective effect of Yerba mate (Ilex paraguariensis) in a Drosophila model of Parkinson ’s disease

    P. Ballestero, A. Bernardi, H. Hauche Pedernera, O. Gershanik, N. Muraro, J. Ferrario (Capital Federal, Argentina)

    Objective: To test the neuroprotective capacity of Yerba Mate (YM) in an in vivo model of Parkinson's disease. Background: Parkinson's disease (PD) is caused by the…
  • 2019 International Congress

    Protective effects of β-Nicotinamide Adenine Dinucleotide against motor deficits and dopaminergic neuronal damage in a Parkinson’s disease mouse model

    C. Shan, YL. Gong, QQ. Zhuang, YF. Hou, SM. Wang, ST. Li, JM. Liu (Shanghai, China)

    Objective: The aim of our study is to explore whether nicotinamide adenine dinucleotide (NAD) replenishment could be beneficial on a 6-hydroxydopamine-induced Parkinson’s disease (PD) mouse…
  • 2019 International Congress

    Relationship between serum uric acid and the pattern of striatal dopamine depletion in De Novo Parkinson’s disease

    K. Baik, Y. Lee, S. Chung, H. Yoo, J. Jung, P. Lee (Seoul, Republic of Korea)

    Objective: To investigate the relationship between serum uric acid (UA) and the pattern of striatal dopamine depletion in drug naïve Parkinson’s disease (PD). Background: UA…
  • 2019 International Congress

    Exploring the experience and challenges for PD STAT clinical trial participants: a qualitative study

    T. North, J. Grose, V. Eyre, D. Webb, R. Chapman, A. Foggo, M. Webber, C. Carroll (Plymouth, United Kingdom)

    Objective: This study aims to identify the reasons why people living with Parkinson’s disease (PD) (PwP) became involved with the PD STAT randomised controlled trial…
  • 2019 International Congress

    Increasing chances of detecting a neuroprotective signal in PhI/II PD clinical trials?

    S. Palfi, C. Denot, A. Bousseau, JC. Corvol (Paris, France)

    Objective: Design an early CT program to detect a neuroprotective signal in PD. Background: Attempts to develop PD modifying therapies have been largely disappointing so…
  • 2019 International Congress

    Utilization patterns of Amantadine in Parkinson’s Disease patients enrolled in the French COPARK study

    S. Perez-Lloret, L. Negre-Pages, P. Damier, A. Delval, P. Derkinderen, A. Destée, W. Meissner, F. Tison, O. Rascol (Bordeaux, France)

    Objective: To explore amantadine IR utilization patterns in the French COPARK study. Background: Immediate release (IR) amantadine is marketed for the treatment of early and…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 15
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley